Hsbc Holdings PLC Has $552,000 Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS

Hsbc Holdings PLC cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 80.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,999 shares of the company's stock after selling 102,829 shares during the quarter. Hsbc Holdings PLC's holdings in Apellis Pharmaceuticals were worth $552,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Assetmark Inc. grew its stake in Apellis Pharmaceuticals by 3,938.7% in the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company's stock valued at $27,000 after acquiring an additional 1,221 shares during the last quarter. GF Fund Management CO. LTD. lifted its position in Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock worth $70,000 after buying an additional 573 shares during the period. Legacy Capital Group California Inc. lifted its holdings in shares of Apellis Pharmaceuticals by 32.8% during the 1st quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company's stock worth $209,000 after acquiring an additional 2,359 shares during the period. Nomura Holdings Inc. purchased a new position in shares of Apellis Pharmaceuticals during the 4th quarter worth about $223,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Apellis Pharmaceuticals by 1,795.4% during the 1st quarter. GAMMA Investing LLC now owns 10,235 shares of the company's stock worth $224,000 after acquiring an additional 9,695 shares during the period. Institutional investors and hedge funds own 96.29% of the company's stock.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 175,037 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $28.19, for a total transaction of $4,934,293.03. Following the transaction, the chief executive officer owned 357,909 shares in the company, valued at $10,089,454.71. This trade represents a 32.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $27.80, for a total value of $139,000.00. Following the transaction, the general counsel owned 123,730 shares in the company, valued at approximately $3,439,694. This trade represents a 3.88% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 399,638 shares of company stock worth $9,910,962. Corporate insiders own 6.50% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on APLS. Mizuho cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a "neutral" rating on the stock in a report on Wednesday, May 14th. JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the company an "overweight" rating in a report on Monday, August 4th. Cantor Fitzgerald lifted their price objective on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Bank of America lifted their price target on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Finally, Wells Fargo & Company lifted their target price on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Monday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $34.12.

Apellis Pharmaceuticals Stock Down 0.7%

NASDAQ APLS traded down $0.20 on Friday, reaching $28.45. The stock had a trading volume of 2,156,156 shares, compared to its average volume of 2,285,338. The company has a market capitalization of $3.59 billion, a price-to-earnings ratio of -15.63 and a beta of 0.73. The business has a 50 day moving average price of $22.75 and a 200 day moving average price of $21.39. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.10 and a 1 year high of $41.94.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The company had revenue of $171.39 million for the quarter, compared to the consensus estimate of $187.91 million. During the same quarter last year, the company posted ($0.30) earnings per share. The company's revenue for the quarter was down 10.6% compared to the same quarter last year. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).